Cargando…
Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic
Nickel et al describe a single-arm trial using dose-escalated hydroxyurea and regular transfusions to prevent complications of sickle cell anemia. Preliminary results suggest that a reduction in volume of red cell requirements may be achievable.
Autores principales: | Nickel, Robert Sheppard, Margulies, Stefanie, Frazer, Brittany, Luban, Naomi L.C., Webb, Jennifer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316219/ https://www.ncbi.nlm.nih.gov/pubmed/32403134 http://dx.doi.org/10.1182/blood.2020006582 |
Ejemplares similares
-
Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic
por: DeBaun, Michael R.
Publicado: (2020) -
Further evidence supporting the global use of hydroxyurea
por: Archer, Natasha M.
Publicado: (2023) -
Transfusion with Tested Bloods
Publicado: (1918) -
Failure of self-disclosure of deferrable risk behaviors associated with transfusion-transmissible infections in blood donors
por: Wong, Horas Tze Hoo, et al.
Publicado: (2015) -
Characterization and first‐in‐human clinical dose‐escalation safety evaluation of a next‐gen human freeze‐dried plasma
por: Cancelas, Jose A., et al.
Publicado: (2021)